{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-23-000020","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.549092+00:00","generated_at":"2026-06-17T06:50:55.067170+00:00","sec_items":["2.03","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Supernus borrows $93M under credit line, repays $402.5M convertible notes due 2023","bullets":["Borrowed $93M from UBS Bank USA on March 30, 2023 under a $150M revolving credit line.","Used proceeds plus available cash to repay the full $402.5M principal and $1.3M interest on its 0.625% Convertible Senior Notes due April 2023.","Credit line is secured by company accounts, securities, and investment property held at UBS.","Following repayment, the 2023 Notes are no longer outstanding."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-23-000020","json":"https://secwatch.observer/filing/0001356576-23-000020.json","markdown":"https://secwatch.observer/filing/0001356576-23-000020.md","text":"https://secwatch.observer/filing/0001356576-23-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000020/0001356576-23-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000020/supn-20230330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T06:50:55.067170+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9429cb9b45cda52cd2de657c3b3224132d3b4330","claim":"SUPERNUS PHARMACEUTICALS, INC. incurred credit facility of $93 million with UBS Bank USA at variable rate.","evidence_excerpt":"On March 30, 2023 the Company borrowed $93 million pursuant to the credit line agreement with UBS Bank USA (\"UBS\") dated as of February 8, 2023 (the \"Credit Line\").","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000020/0001356576-23-000020-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"$93 million"},{"label":"Counterparty","value":"UBS Bank USA"},{"label":"Rate","value":"variable rate"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}